Eric Aian Pereira da Silva

Eric Aian Pereira da Silva

Auto-generated profile, based on publicly available information

Eric Aian Pereira da Silva

Department of Pharmacology, University of California Davis, Davis, CA (J.H., M.M.-A.B., S.I.N., J.T., Y. Mohabbat, Y. Moustafa, E.P.D.S., Z.Z., N.D.-R., G.R.R., Y.K.X., M.N.-C., M.F.N.).

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 December 2018 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
ESEric Aian P. Silva
Eric Aian P. Silva
JCJéssica S. Carvalho
Jéssica S. Carvalho
AGAdriana Guimarães
Adriana Guimarães
RBRosana de S.S. Barreto
Rosana de S.S. Barreto
MSMárcio R.V. Santos
Márcio R.V. Santos
LQLucindo Quintans-Junior
Lucindo Quintans-Junior
Introduction: Terpenes are a class of secondary metabolites that can be found in a variety of animal and plants species. They are considered the most structurally diversified and abundant of all natural compounds. Several studies have shown the application of terpenes, such as carvacrol, linalool, and limonene in many pharmaceutical and medicinal fields, including cardiovascular disorders, the leading cause of death worldwide. Areas covered: In this review, the authors outlined patents from the last 10 years relating to the therapeutic application of terpenes for the treatment and/or prevention of cardiovascular diseases found in different databases, emphasizing the possibility of these compounds becoming new drugs that may help to decrease the burden of these disorders. Expert opinion: There has been a growing awareness over recent years of the therapeutic use of terpenes and their derivatives as new pharmaceutical products. Patents involving the use of terpenes have been especially important in the technological development of new strategies for the treatment of cardiovascular diseases by bringing new scientific knowledge into the pharmaceutical industry. Therefore, the development of biotechnologies using natural products should be encouraged in order to increase the variety of drugs available for the treatment of cardiovascular diseases.

20 April 2022 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
YMYandra Y.M. Marinho
Yandra Y.M. Marinho
ESEric Aian P. Silva
Eric Aian P. Silva
JOJeferson Y.S. Oliveira
Jeferson Y.S. Oliveira
DSDanillo M. Santos
Danillo M. Santos
BLBruno S. Lima
Bruno S. Lima
MSMarcio R.V. Santos
Marcio R.V. Santos

12 June 2022 in Phytomedicine Plus
Verified
Journal Article
Open access
HSHericalizandra Santa Rosa Santana
Hericalizandra Santa Rosa Santana
FCFernanda Oliveira de Carvalho
Fernanda Oliveira de Carvalho
DSDanillo Menezes dos Santos
Danillo Menezes dos Santos
ESEric Aian Pereira da Silva
Eric Aian Pereira da Silva
ÉSÉrika Ramos Silva
Érika Ramos Silva
MSMárcio Roberto Viana dos Santos
Márcio Roberto Viana dos Santos

15 August 2025 in Circulation Research
Verified
Journal Article
Open access
JHJunyoung Hong
Junyoung Hong
MBMiguel Martin Aragon Baudel
Miguel Martin Aragon Baudel
SNSayeman Islam Niloy
Sayeman Islam Niloy
JTJade Taylor
Jade Taylor
YMYaseen Mohabbat
Yaseen Mohabbat
MNManuel F. Navedo
Manuel F. Navedo
BACKGROUND: Diabetic hyperglycemia promotes vasoconstriction by activating an ATP-dependent P2Y 11L (P2Y 11 -like receptor)/AC5 (adenylyl cyclase 5)/AKAP5 (A-kinase anchoring protein 5)/PKA (protein kinase A)/Ca V 1.2 (L-type voltage-dependent calcium channel 1.2) nanocomplex in arterial myocytes, but upstream mechanisms are unclear. We hypothesized that Panx1 (pannexin 1) channels, which facilitate ATP release, are associated with the complex in arterial myocytes and mediate its activation to induce vasoconstriction during diabetic hyperglycemia. METHODS: Multidisciplinary approach using extracellular ATP and cAMP biosensors, patch-clamp electrophysiology, super-resolution nanoscopy, proximity ligation assay, pressure myography, and laser speckle imaging to test premises in arterial myocytes and vessels from wild-type and genetically modified mice, including an inducible smooth muscle–specific Panx1 knockout and a global AKAP5 knockout. RESULTS: We found that elevating extracellular glucose (eg, high glucose, hyperglycemia) triggered an increase in extracellular ATP levels, and this was reduced in the presence of the Panx1 inhibitor spironolactone, in inducible smooth muscle–specific Panx1 knockout cells, and by inhibiting glucose metabolism. Panx1 was found in complex with P2Y 11L , AC5, AKAP5, PKA, and Ca V 1.2 in arterial myocytes. The protein complex was strengthened in response to hyperglycemia, which required Panx1 and AKAP5. Hyperglycemia–induced cAMP production, Ca V 1.2 potentiation, sustained vasoconstriction, and in vivo changes in cerebral artery myogenic tone and blood flow were ameliorated by spironolactone and in inducible smooth muscle–specific Panx1 knockout samples. Panx1 expression was elevated in arterial lysates from a mouse model of type 1 diabetes (eg, streptozotocin), and increased Ca V 1.2 activity and enhanced ex vivo and in vivo myogenic tone were prevented in arterial myocytes and arteries from inducible smooth muscle–specific Panx1 knockout mice. CONCLUSIONS: These results suggest a key role for Panx1 in controlling ATP signaling through the P2Y 11L /AC5/AKAP5/PKA/Ca V 1.2 axis in arterial myocytes. This Panx1-led complex modulates cAMP levels, Ca V 1.2 activity, and vascular reactivity in response to diabetic hyperglycemia. Thus, Panx1 could be a new therapeutic target to mitigate vascular complications during diabetes.

10 November 2020 in Natural Product Research
Verified
Journal Article
Closed access
BSBianca Leite Santos
Bianca Leite Santos
AOAllan John de Oliveira
Allan John de Oliveira
ISIzabelly Vieira Santos
Izabelly Vieira Santos
MDMarcelo Cavalcante Duarte
Marcelo Cavalcante Duarte
PCPatrícia Santos Cunha
Patrícia Santos Cunha
MSMárcio Roberto Viana dos Santos
Márcio Roberto Viana dos Santos
Species of Erythroxylum genus are popularly used as anti-inflammatories and in the treatment of renal and respiratory disorders. Although it has been reported that species from the Erythroxylum genus induce cardiovascular effects, E. passerinum had not been studied specifically in this respect. However, previous phytochemical studies of E. passerinum demonstrated the presence of compounds which can have potential activity on the cardiovascular system. In this study, phytochemical screening of the ethanol extract of E. passerinum (EEEP) detected polyphenols, but not alkaloids. EEEP caused hypotension, bradycardia and vasorelaxation in rats. The vasorelaxation was attenuated by Nw-nitro-L-arginine methyl ester (L-NAME) or L-NAME + indomethacin (INDO), but not by INDO alone. Vasorelaxation was also significantly attenuated after endothelium removal or after incubation with high K+, 4-aminopyridine, glibenclamide or tetraethylammonium, but was not affected by pre-contraction with serotonin. Thus, EEEP induces hypotension and endothelium-dependent and independent vasorelaxation, which seems to involve the nitric oxide and K+-channels. Graphical abstract

31 October 2019 in Saudi Journal of Biomedical Research
Verified
Journal Article
Closed access
JNJosé Marden Mendes Neto
José Marden Mendes Neto
RARicardo Guimarães Amaral
Ricardo Guimarães Amaral
MMMaria Iolanda Amaral Maia
Maria Iolanda Amaral Maia
SSSara Albuquerque dos Santos
Sara Albuquerque dos Santos
ESEric Aian Pereira da Silva
Eric Aian Pereira da Silva
SSSandra Lauton Santos
Sandra Lauton Santos